HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong, China.
World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong, China.
Viruses. 2021 Sep 6;13(9):1779. doi: 10.3390/v13091779.
Next generation influenza vaccines that target conserved epitopes are becoming a clinical reality but still have challenges to overcome. Universal next generation vaccines are considered a vital tool to combat future pandemic viruses and have the potential to vastly improve long-term protection against seasonal influenza viruses. Key vaccine strategies include HA-stem and T cell activating vaccines; however, they could have unintended effects for virus adaptation as they recognise the virus after cell entry and do not directly block infection. This may lead to immune pressure on residual viruses. The potential for immune escape is already evident, for both the HA stem and T cell epitopes, and mosaic approaches for pre-emptive immune priming may be needed to circumvent key variants. Live attenuated influenza vaccines have not been immunogenic enough to boost T cells in adults with established prior immunity. Therefore, viral vectors or peptide approaches are key to harnessing T cell responses. A plethora of viral vector vaccines and routes of administration may be needed for next generation vaccine strategies that require repeated long-term administration to overcome vector immunity and increase our arsenal against diverse influenza viruses.
针对保守表位的下一代流感疫苗正逐渐成为临床现实,但仍面临诸多挑战需要克服。通用的下一代疫苗被认为是应对未来大流行病毒的重要工具,有潜力极大地提高对季节性流感病毒的长期保护效果。关键的疫苗策略包括血凝素(HA)茎和 T 细胞激活疫苗;然而,由于它们在细胞进入后识别病毒,而不是直接阻止感染,因此可能对病毒的适应性产生意外影响。这可能会对残留病毒产生免疫压力。HA 茎和 T 细胞表位的免疫逃逸潜力已经很明显,因此可能需要抢先免疫预刺激的马赛克方法来规避关键变异。减毒活流感疫苗在具有既定既往免疫的成年人中不足以刺激 T 细胞产生免疫应答。因此,病毒载体或肽方法是利用 T 细胞反应的关键。下一代疫苗策略需要重复长期给药,以克服载体免疫并增加我们对抗多种流感病毒的武器库,因此可能需要多种病毒载体疫苗和给药途径。